Cantor Fitzgerald Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Stock analysts at Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note issued on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $10.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 165.96% from the company’s previous close.

A number of other research firms have also recently commented on TLSI. Roth Mkm began coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They issued a “buy” rating and a $11.00 price target for the company. Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Northland Securities started coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $11.79.

TriSalus Life Sciences Trading Down 1.3 %

Shares of TLSI opened at $3.76 on Tuesday. The firm has a market cap of $114.65 million, a PE ratio of -1.51 and a beta of 0.56. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42. The stock has a fifty day moving average price of $4.16 and a 200-day moving average price of $4.97.

Institutional Trading of TriSalus Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences in the third quarter valued at $92,000. Geode Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the last quarter. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences in the third quarter worth about $108,000. MSD Partners L.P. acquired a new stake in TriSalus Life Sciences during the third quarter worth about $184,000. Finally, Walleye Capital LLC purchased a new position in TriSalus Life Sciences during the third quarter valued at approximately $66,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.